2010

Implantable Neurostimulator Project Transformation at Institute of Microelectronics, Tsinghua University.

2013

Established Rishena Medical.

Invested by Tsinghua Venture Capital and other venture funds.

Awarded Dragon City Talent.

2014

Built a 100,000-class clean plant.

Awarded Jiangsu Province Shuangchuang Talent.

2015

VNS initiate clinical trials.

Received Innovation Fund of Jiangsu Province.

2016

SEEG、SCS project development.

Awarded SCS National Key R & D Program Project as the lead unit.

2017

VNS in clinical trials.

Awarded Jiangsu Province Double Innovation Team.

2018

SEEG launches clinical trial.

National Key Research and Development Program of China (Neuromodulation of Alzheimer 's Disease).

2019

SCS initiates clinical trials.

Received the National Key Research and Development Program (Neuromodulation of depression).

2020

VNS approved for marketing.

2021

SEEG approved for marketing.

t-VNS approved for marketing.

Awarded the Science and Technology Innovation 2030 "Brain Science and Brain-like Research" Major Program.

Obtained Jiangsu Province Key R&D Program Project (Implantable Adjuvant Drug Infusion System).

2022

SCS approved for marketing.

CNS launches clinical trial.

Units Selected to Unveil Artificial Intelligence Medical Device Innovation Mission.

2023

Micropush approved for marketing.

Selected as a potential unicorn in Jiangsu Province 2023.

2024

Second generation of t-VNS approved for marketing.

Selected as Jiangsu Provincial Specialized and Sophisticated Small and Medium-sized Enterprise.

2025

Implantable Neurostimulation system（CNS） approved for marketing.

Implantable Access Port approved for marketing.

Obtained the 2025 National Key R&D Program "Common and Frequent Diseases Prevention and Treatment Research".